LONDON – In the most competitive year of OneStart yet, the 20 finalist startups – 10 from the Americas, and 10 from Europe and the rest of the world – have now been selected by our expert judging panel. Each of our 70 semi-finalist startups (click here to watch their video pitches) have experienced an intensive two-day Biotech Bootcamp in February and worked with experienced mentors for an intensive 6-week period to help them prepare a 5-page business plan and 10-slide investor pitch deck.
The selected finalists have stood out from over 630 life science and health care applicant startups worldwide, and have shown the most incredible growth out of the semi-finalists in the past few months of mentoring and training. “The best thing about OneStart,” said Matthew Foy, Partner at SR One, “is being able to access networks of people who have done it before, and are willing to give you their time.”
These 20 finalist startups are working on a broad range of disruptive ideas, from elegant devices to replace dated yet commonplace clinical procedures, to time-saving diagnostic solutions for hospitals and patients, to innovative molecular therapeutics for diseases that have challenged researchers for decades.
SR One and the Oxbridge Biotech Roundtable (OBR) co-founded OneStart with mentorship as its core component. “We want to give these talented, young entrepreneurs a head start with our mentors’ decades of experience,” said Daniel Perez, CEO & Founder of OBR. “If you mentor someone, and you see progress in a very short amount of time, it’s a beautiful thing,” Jens Eckstein, President of SR One remarked.
Almost 200 experienced entrepreneurs, investors, and industry professionals, including mentors from our partners Johnson & Johnson Innovation, Takeda Ventures, Bristol-Myers Squibb, GSK, Roche, McKinsey, AstraZeneca, Silicon Valley Bank, MedCity, Forresters and Olswang, have supported the OneStart semi-finalists this year.
“Innovation is best nurtured by the people who came up with the idea, and what we can bring them is the skill sets to help them do that.” commented Jeanne Bolger, VP Venture Investing at Johnson & Johnson Innovation – JJDC and speaker at the London Bootcamp.
“Nurturing this entrepreneurial ecosystem is beneficial to everybody in the long run,” said Ilan Zipkin, Senior Investment Director at Takeda Ventures and mentor of two OneStart teams this year. “The learning from their interactions here will help them, and it will help us to understand what are the trends overall and what are the important investment themes for us to go into,” commented Matthias Essenpreis, CTO of Roche Diagnostics and OneStart mentor.
“OneStart is an amazing way for up and coming entrepreneurs to have direct interactions with future decision makers,” said Lynne Murray, Partnering & Strategy, MedImmune, OneStart mentor and panellist at the London Bootcamp. “The programme provides a unique opportunity for entrepreneurs, at an early stage of their career, to present to an audience of seasoned biotech and pharma leaders, and at the same time, this audience gets direct insight in to novel ways of thinking that are emerging from academic research.”
“OneStart offers a fantastic range of expertise,” Sarah Haywood, COO of MedCity remarked, “We have people here who have worked with successful multinational companies and the NHS, lawyers, financial experts and more.” “We see it as a responsibility of ours to find those leaders, those fresh new companies of tomorrow with exciting ideas,” expressed Nooman Haque, Director of Life Sciences at Silicon Valley Bank. Both Sarah and Nooman spoke at the London Bootcamp.
“One piece of advice for young entrepreneurs that I would have is quite simply – join OneStart,” said Thorsten Melcher, Senior Director for New Ventures at Johnson & Johnson Innovation, California, OneStart mentor and speaker at the San Francisco Bootcamp , “It is a very, very tough road to start a company, to pull a team together, to be knowledgeable in the legal, financial and business aspects, and OneStart is a fantastic medium to help people accomplish that.”
Find out more about how you can get involved in OneStart 2016 at onestart.co, and meet this year’s finalists and mentors in person at the:
• OneStart Europe Finals Gala, London, 14 May 2015 (click here to register), or
• OneStart Americas Finals Gala, San Francisco, 21 May 2015 (click here to register)
Click on the team names below to view their 1-min pitch, or browse on the OneStart website.
Blue Therapeutics – Cambridge, MA, United States
Advancing a novel small molecule that relieves pain without creating addiction
Cogentis Therapeutics – Baltimore, MD, United States
A novel and potential disease-modifying peptide therapeutic for Alzheimer’s, ALS, and Parkinson’s
Empire Biotechnologies – San Francisco, CA, United States
We have a patent-pending biological therapeutic that can enhance nutrient absorption and treat diseases of malabsorption
ImmunoMatrix – Stony Brook, NY, United States
Immunomatrix provides people who are suffering from allergies a painless and convenient immunotherapeutic treatment
Ligadon – Murray, UT, United States
Ligadon provides a simple and effective device for treating ligament and tendon injuries.
Molecular Cosmetics – Stanford, CA, United States
A bioactive-lotion that enables you to tan without sun exposure and reduces skin cancer risk by harnessing the body’s natural defenses
Myelin Therapeutics – San Francisco, CA, United States
Natural and synthetic molecules that promote brain repair for demyelinating and neurodegenerative pathologies
Phase Diagnostics – Los Angeles, CA, United States
Honesti: A handheld, one-step, self-diagnostic for sexually transmitted infections (STI)
Riparian Pharmaceuticals – Boston, MA, United States
Discovering therapeutics to improve vascular health in cardiovascular, diabetic and inflammatory diseases
SmartLens – Stanford, CA, United States
Lens with intraocular pressure (IOP) monitoring device which can be read with a smartphone
BeamLine Diagnostics – London, United Kingdom
Software to enable rapid, quantitative diagnosis of normal, pre-cancerous and cancerous biopsies
BioMe – Oxford, United Kingdom
An ingestible gut sampling device that will improve the diagnostics of gastrointestinal disorders
Cambridge Cardiology – Cambridge, United Kingdom
The first removable transcatheter heart valve
Circulus Therapeutics – Oxford, United Kingdom
Exploiting the safety, stability and efficiency of circular RNAs as novel vectors for transient gene replacement therapy
InspiWave – Oxford, United Kingdom
InspiWave fills the gap between outdated spirometery/plethysmography and costly imaging techniques for lung testing
Keregen – London, United Kingdom
Keregen develops innovative medicines that preserve cell quality, prevent neurodegeneration and promote longevity
ShyDen Biotech – London, United Kingdom
Widening therapeutic windows via activatable antibodies
Syndivia – Strasbourg, France
Creating better biotherapeutics for unmet clinical needs
T.I.G.R – Tel Aviv, Israel
A revolutionary tourniquet to help inexperienced people dealing with uncontrolled bleeding related to limb injuries
UroLogic – Cambridge, United Kingdom
A novel shape memory indwelling catheter device to reduce hospital associated urinary-tract infections
OneStart is the world’s largest life sciences and health care business plan accelerator programme, welcoming ideas from across the spectrum, from therapeutics and diagnostics to software, medical devices and research tools. The OneStart initiative was founded in 2012 by the Oxbridge Biotech Roundtable and SR One.
Each year, 35 semi-finalist teams from each of two parallel streams, Americas and Europe (including the rest of the world), are chosen to attend the Biotech Bootcamps in February 2015 and undertake 6 weeks of intensive mentoring with over 100 top industry experts to hone their business plan and investors’ pitch deck. A selection of our 2015 mentors are listed at: onestart.co/mentors
The top 10 teams from each region are then selected to pitch at the Finals Galas in May 2015 during which the most exceptional team for the Americas and Europe streams is awarded a non-dilutive grand prize of £100k/$150k and free lab space, with no strings attached. Applications to OneStart are completely free-of-charge and all participants retain full control and ownership of their business.
Partners of OneStart 2015 are Johnson & Johnson Innovation, Takeda Ventures, Bristol-Myers Squibb, GSK, McKinsey & Company, Roche, MedCity, AstraZeneca, Silicon Valley Bank, Forresters, and Olswang.
Learn more about OneStart at onestart.co
Learn more about past OneStart finalists at onestart.co/startups
About the Oxbridge Biotech Roundtable
The Oxbridge Biotech Roundtable (OBR) is a global platform for innovators that aims to bridge the gap between industry and academia to move ideas forward in health care and the life sciences.
OBR founded OneStart together with SR One in order to unlock and facilitate latent entrepreneurship in younger scientists. By marrying generous financial support with deep industry experience OBR hopes that OneStart sets many dozens of companies in motion each year, each positively impacting human health. Find out more at oxbridgebiotech.com
About SR One
SR One is the corporate venture capital arm of GSK. The firm invests globally in emerging life science companies that are pursuing innovative science with significant impact on medical care. SR One has invested over $830 million in the biotech space.
SR One teamed up with the Oxbridge Biotech Roundtable (OBR) because of their shared missions of catalysing entrepreneurship. Together with OBR, SR One firmly believes that they can have a positive impact on human health by supporting visionary founders, with OneStart as a vehicle to that end. Find out more at srone.com